



# STATE OF CONNECTICUT

## DEPARTMENT OF PUBLIC HEALTH

### CLINICAL ADVISORY:

### EXPEDITED PARTNER THERAPY (EPT) FOR CHLAMYDIA AND GONORRHEA INFECTION IN CONNECTICUT

OCTOBER 1, 2011

CONNECTICUT DEPARTMENT OF PUBLIC HEALTH (CDPH)

Expedited partner therapy (EPT) is the practice of treating the sex partners of persons diagnosed with chlamydia or gonorrhea infection without first examining or testing the partner. EPT helps interrupt the spread of disease by getting treatment to people who might otherwise remain untreated. As of October 1, 2011, Public Act 11-242 authorizes prescribing practitioners to prescribe or dispense antibiotics to treat chlamydia and/or gonorrhea infection in the sex partners of patients with chlamydia and/or gonorrhea infection. A practitioner who prescribes or dispenses antibiotics in this manner does not violate the practitioner's standard of care. The law defines a "prescribing practitioner" as a physician, dentist, podiatrist, optometrist, physician assistant, advanced practice registered nurse (APRN), nurse-midwife, or veterinarian licensed in Connecticut to prescribe medicine within his or her scope of practice.

#### Background on Chlamydia and Gonorrhea Infection and EPT

Chlamydia and gonorrhea infections are the most common reported sexually transmitted diseases (STD) in the United States. In Connecticut in 2010, there were 12,694 chlamydia infections and 2,568 gonorrhea infections reported. The incidence of reported chlamydia and gonorrhea infections in Connecticut among adolescents (ages 15–19) and young adults (ages 20–24) was 2,207 and 381 per 100,000 respectively.

Despite their prevalence, chlamydia and gonorrhea infections are often undiagnosed because infected individuals are asymptomatic. Patients with chlamydia and gonorrhea infection are at increased risk for reinfection after treatment if their sex partners are not also treated. EPT helps prevent reinfection by increasing the likelihood that sex partners are effectively treated, even if they are unwilling or unable to seek medical care on their own. This is particularly true for adolescents, who may be afraid to seek medical care or disclose their infection to their parents.

EPT has been shown to be safe and effective in the treatment of sex partners. Research has demonstrated that EPT is effective in reducing reinfection of index case-patients infected with chlamydia or gonorrhea. Several states with long-standing EPT programs have had no reports of adverse events.

#### Treatment Protocol<sup>1</sup>

The recommended treatment for chlamydia and gonorrhea infection when using EPT are the following:

---

<sup>1</sup> CDC, *Sexually Transmitted Diseases Treatment Guidelines*, MMWR 59 (RR12) 45, (Dec. 17, 2010).



Telephone Device for the Deaf: (860) 509-7191

410 Capitol Avenue, MS# \_\_\_\_\_

P.O. Box 340308 Hartford, CT 06134

*Affirmative Action/An Equal Opportunity Employer*

- For chlamydia infection, one oral dose of 1g of azithromycin
- For gonorrhea infection, one oral dose of 400mg of cefixime **and** one oral dose of 1g of azithromycin
- For chlamydia and gonorrhea infection, one oral dose of 400mg of cefixime **and** one oral dose of 1g of azithromycin

This is the recommended first line treatment for both patients with known chlamydia and/or gonorrhea infection and their sex partners, adults and adolescents, 13 years of age and older. The single dose enhances adherence with directly observed and unobserved therapy.

Because second line treatments for these infections often require multiple doses of medication over several days and can be associated with more adverse events, they are not recommended for EPT.

EPT should be used with caution for partners of patients with gonorrhea and oral exposure as cefixime has less penetration into the oral cavity compared to ceftriaxone, the preferred first line treatment for gonorrhea.

### Implementation Options

There have been no published studies demonstrating the efficacy of EPT in the treatment of chlamydia or gonorrhea infection in the male sex partners of males with these infections. Therefore, current Centers for Disease Control and Prevention (CDC) guidelines for the treatment of sexually transmitted infections recommend EPT for use in heterosexual men and women with chlamydia or gonorrhea infection only.

CDPH recommends the following option for the prescribing practitioner implementing EPT:

- Provide a written prescription for a named sex partner(s) of the infected patient;
- Dispense the medication directly, one dose to be taken immediately by the patient, and an additional dose or doses to be delivered by the patient to the sex partner(s). A separate, properly labeled container is to be used for the dose(s) for each sex partner.

### Patient Counseling and Information for Partners

Patients with chlamydia and/or gonorrhea infection should be counseled to abstain from sex (this includes oral, anal, or genital sex, with or without condoms) for seven days after completion of therapy, notify their sex partners about their infection, and avoid future infection by using condoms during sex.

**Regardless of which EPT implementation option the practitioner chooses, the written prescription or medication for the partner should be accompanied by a partner information sheet (whenever possible).** An example of such a document is attached, and contains information about exposure to chlamydia and/or gonorrhea, the need for treatment, instructions about treatment and potential allergic reactions, and the need for abstaining from sex for seven days following treatment. This information sheet should be included with each dose or prescription given to the patient for their partners.

### Conclusions

Successful EPT programs in other states have demonstrated that EPT is both safe and effective for preventing reinfection in patients with chlamydia or gonorrhea infection. The use of EPT is entirely voluntary and CDPH continues to encourage all sex partners to seek clinical care

regardless of whether EPT is used. However, CDPH recommends that health care providers use EPT when, in their clinical judgment, it would be beneficial for both the patient and the sex partner(s).

## References and Resources for Health Care Providers

1. CDC, Expedited Partner Therapy in the Management of Sexually Transmitted Diseases: Review and Guidance (2006). <http://cdc.gov/std/treatment/EPTFinalReport2006.pdf>
2. American Medical Association, Expedited Partner Therapy (Patient-delivered Partner Therapy): An Update (2006). <http://www.ama-assn.org/ama/no-index/about-ama/16410.shtml>
3. American Bar Association, resolution supporting removal of legal barriers to the provision of EPT (August 15, 2008). Available at <http://cdc.gov/std/ept/>
4. Matthew R. Golden, et al., *Effect of Expedited Treatment of Sex Partners on Recurrent or Persistent Gonorrhea or Chlamydial Infection*, N Eng J Med, 2005;352:676-85.
5. Matthew R. Golden, *Expedited Partner Therapy: Moving from Research to Practice*, Sex Transm Dis, 2008;35:320-22.
6. Julia A. Schillinger et al., *Patient-Delivered Partner Treatment with Azithromycin to Prevent Repeated Chlamydia trachomatis Infection Among Women*, Sex Transm Dis, 2003;30:49-56.
7. K. McBride, et al., *Formative Design and Evaluation of Patient-Delivered Partner Therapy Informational Materials and Packaging*, Sex Transm Infect, 2009;85:150-155.
8. James G. Hodge, et al., *Expedited Partner Therapy for Sexually Transmitted Diseases: Assessing the Legal Environment*, Am J Public Health, 2008;98(2): 238–243.
9. Patricia Kissinger, *Considering the Patient in Patient-Delivered Partner Therapy*, Sex Transm Inf, 2009;85:80-81.
10. *Expedited Partner Therapy for Adolescents Diagnosed with Chlamydia or Gonorrhea: A Position Paper of the Society for Adolescent Medicine*, J Adol Health, 2009;45:303-309. (Supported by the American Academy of Pediatrics.)
11. American College of Obstetrics and Gynecologists Opinion on EPT to Prevent STI Reinfection (August 22, 2011). Available at <http://cdc.gov/std/ept/>